Table 4B.

IL-6 by study arm—adjusted analysis.

	Visits
	Unadjusted means			Unadjusted difference in means
Markers	T0 95% CI	T6 95% CI	T12 95% CI	T0 95% CI p-Value	T6 95% CI p-Value	T12 95% CI p-Value	p-Value*
IL-6, pg/mL
RCT arm							0.487
DTG/3TC	2.6 (1.9, 3.3)	2.7 (2.0, 3.4)	2.5 (1.8, 3.2)	0	0	0
B/F/TAF	2.4 (1.7, 3.1)	3.1 (2.3, 3.8)	3.0 (2.3, 3.7)	−0.2 (−1.2, 0.8)	0.4 (−0.6, 1.4)	0.5 (−0.5, 1.5)
				0.728	0.484	0.326
IL-6 (change) by study arm—adjusted analysis.
	Visits
	Adjusted means			Adjusted difference in means
Markers	T0 95% CI	T6 95% CI	T12 95% CI	T0 95% CI p-Value	T6 95% CI p-Value	T12 95% CI p-Value	p-Value*
IL-6, pg/mL
RCT arm							0.504
DTG/3TC	0.0 (−0.6, 0.6)	0.2 (−0.4, 0.8)	−0.0 (−0.7, 0.6)	0	0	0
B/F/TAF	−0.0 (−0.7, 0.6)	0.6 (−0.0, 1.3)	0.6 (−0.1, 1.3)	−0.0 (−1.0, 0.9)	0.4 (−0.5, 1.3)	0.6 (−0.3, 1.6)
				0.931	0.399	0.180

^* F-test type 3 interaction p-value.

RCT, randomized clinical trial; VL, viral load.

^* F-test type 3 interaction p-value.

^& Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD4 count nadir.